News

RICH Europe survey on the needs and challenges of stakeholders participating in Horizon Europe Research Infrastructures Work Programme

Published on | 1 month ago

Programmes RI

The NCP network for research infrastructures RICH Europe has launched a survey to better understand the requirements and difficulties that stakeholders face in the Work Programme of the Research Infrastructures of Horizon Europe. The feedback and answers from the survey will be used for enhancing the activities and services that RICH Europe provides and will not only benefit the National Contact Points (NCPs) but will also serve the interests of all stakeholders involved. By understanding their needs and preferences, the RICH Europe project can implement improvements that will lead to more effective and engaging initiatives for everyone.

The survey is open to RIs National Contact Points, researchers and other stakeholders. Deadline for filling in the survey is 25 April 2025. Link to the survey.

myOverview - sign up for personalised information

We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).

Stay informed about what matters to you. By signing up, you can opt in for e-mail notifications and get access to a personalised dashboard that groups all news updates and event announcements in your domain(s).

Only for stakeholders located in Flanders

Latest News

1601 articles available search in articles 

Testimonial

image of Methylomic – Hope & Improved outcomes for Crohn’s disease patients across Europe

Methylomic – Hope & Improved outcomes for Crohn’s disease patients across Europe

The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.